Daily testing for contacts of individuals with SARS-CoV-2 infection and attendance and SARS-CoV-2 transmission in English secondary schools and colleges: an open-label, cluster-randomised trial.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
02 10 2021
Historique:
received: 29 07 2021
revised: 17 08 2021
accepted: 19 08 2021
pubmed: 18 9 2021
medline: 12 10 2021
entrez: 17 9 2021
Statut: ppublish

Résumé

School-based COVID-19 contacts in England have been asked to self-isolate at home, missing key educational opportunities. We trialled daily testing of contacts as an alternative to assess whether this resulted in similar control of transmission, while allowing more school attendance. We did an open-label, cluster-randomised, controlled trial in secondary schools and further education colleges in England. Schools were randomly assigned (1:1) to self-isolation of school-based COVID-19 contacts for 10 days (control) or to voluntary daily lateral flow device (LFD) testing for 7 days with LFD-negative contacts remaining at school (intervention). Randomisation was stratified according to school type and size, presence of a sixth form, presence of residential students, and proportion of students eligible for free school meals. Group assignment was not masked during procedures or analysis. Coprimary outcomes in all students and staff were COVID-19-related school absence and symptomatic PCR-confirmed COVID-19, adjusted for community case rates, to estimate within-school transmission (non-inferiority margin <50% relative increase). Analyses were done on an intention-to-treat basis using quasi-Poisson regression, also estimating complier average causal effects (CACE). This trial is registered with the ISRCTN registry, ISRCTN18100261. Between March 18 and May 4, 2021, 204 schools were taken through the consent process, during which three decided not to participate further. 201 schools were randomly assigned (control group n=99, intervention group n=102) in the 10-week study (April 19-May 10, 2021), which continued until the pre-appointed stop date (June 27, 2021). 76 control group schools and 86 intervention group schools actively participated; additional national data allowed most non-participating schools to be included in analysis of coprimary outcomes. 2432 (42·4%) of 5763 intervention group contacts participated in daily contact testing. There were 657 symptomatic PCR-confirmed infections during 7 782 537 days-at-risk (59·1 per 100 000 per week) in the control group and 740 during 8 379 749 days-at-risk (61·8 per 100 000 per week) in the intervention group (intention-to-treat adjusted incidence rate ratio [aIRR] 0·96 [95% CI 0·75-1·22]; p=0·72; CACE aIRR 0·86 [0·55-1·34]). Among students and staff, there were 59 422 (1·62%) COVID-19-related absences during 3 659 017 person-school-days in the control group and 51 541 (1·34%) during 3 845 208 person-school-days in the intervention group (intention-to-treat aIRR 0·80 [95% CI 0·54-1·19]; p=0·27; CACE aIRR 0·61 [0·30-1·23]). Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission, with similar rates of symptomatic infections among students and staff with both approaches. Infection rates in school-based contacts were low, with very few school contacts testing positive. Daily contact testing should be considered for implementation as a safe alternative to home isolation following school-based exposures. UK Government Department of Health and Social Care.

Sections du résumé

BACKGROUND
School-based COVID-19 contacts in England have been asked to self-isolate at home, missing key educational opportunities. We trialled daily testing of contacts as an alternative to assess whether this resulted in similar control of transmission, while allowing more school attendance.
METHODS
We did an open-label, cluster-randomised, controlled trial in secondary schools and further education colleges in England. Schools were randomly assigned (1:1) to self-isolation of school-based COVID-19 contacts for 10 days (control) or to voluntary daily lateral flow device (LFD) testing for 7 days with LFD-negative contacts remaining at school (intervention). Randomisation was stratified according to school type and size, presence of a sixth form, presence of residential students, and proportion of students eligible for free school meals. Group assignment was not masked during procedures or analysis. Coprimary outcomes in all students and staff were COVID-19-related school absence and symptomatic PCR-confirmed COVID-19, adjusted for community case rates, to estimate within-school transmission (non-inferiority margin <50% relative increase). Analyses were done on an intention-to-treat basis using quasi-Poisson regression, also estimating complier average causal effects (CACE). This trial is registered with the ISRCTN registry, ISRCTN18100261.
FINDINGS
Between March 18 and May 4, 2021, 204 schools were taken through the consent process, during which three decided not to participate further. 201 schools were randomly assigned (control group n=99, intervention group n=102) in the 10-week study (April 19-May 10, 2021), which continued until the pre-appointed stop date (June 27, 2021). 76 control group schools and 86 intervention group schools actively participated; additional national data allowed most non-participating schools to be included in analysis of coprimary outcomes. 2432 (42·4%) of 5763 intervention group contacts participated in daily contact testing. There were 657 symptomatic PCR-confirmed infections during 7 782 537 days-at-risk (59·1 per 100 000 per week) in the control group and 740 during 8 379 749 days-at-risk (61·8 per 100 000 per week) in the intervention group (intention-to-treat adjusted incidence rate ratio [aIRR] 0·96 [95% CI 0·75-1·22]; p=0·72; CACE aIRR 0·86 [0·55-1·34]). Among students and staff, there were 59 422 (1·62%) COVID-19-related absences during 3 659 017 person-school-days in the control group and 51 541 (1·34%) during 3 845 208 person-school-days in the intervention group (intention-to-treat aIRR 0·80 [95% CI 0·54-1·19]; p=0·27; CACE aIRR 0·61 [0·30-1·23]).
INTERPRETATION
Daily contact testing of school-based contacts was non-inferior to self-isolation for control of COVID-19 transmission, with similar rates of symptomatic infections among students and staff with both approaches. Infection rates in school-based contacts were low, with very few school contacts testing positive. Daily contact testing should be considered for implementation as a safe alternative to home isolation following school-based exposures.
FUNDING
UK Government Department of Health and Social Care.

Identifiants

pubmed: 34534517
pii: S0140-6736(21)01908-5
doi: 10.1016/S0140-6736(21)01908-5
pmc: PMC8439620
pii:
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1217-1229

Subventions

Organisme : Medical Research Council
ID : MR/W02067X/1
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests DWE reports lecture fees from Gilead outside the submitted work. VB, RO, and DC are consultants employed by Department of Health and Social Care as part of Deloitte's broader project work supporting the delivery of NHS Test and Trace. TF reports honoraria from Qatar National Research Fund outside the submitted work. All other authors declare no competing interests.

Références

N Engl J Med. 2018 Oct 4;379(14):1322-1331
pubmed: 30281988
Lancet Infect Dis. 2021 Mar;21(3):344-353
pubmed: 33306981
Lancet Infect Dis. 2017 Feb;17(2):207-214
pubmed: 27863959
Clin Infect Dis. 2022 Feb 11;74(3):407-415
pubmed: 33972994
Lancet Public Health. 2021 Mar;6(3):e175-e183
pubmed: 33484644
Clin Infect Dis. 2021 Nov 2;73(9):e2861-e2866
pubmed: 33479756
EClinicalMedicine. 2021 Aug;38:101011
pubmed: 34278276
Cochrane Database Syst Rev. 2020 Aug 26;8:CD013705
pubmed: 32845525
BMJ. 2021 Mar 31;372:n608
pubmed: 33789843
BMJ Paediatr Open. 2020 May 4;4(1):e000701
pubmed: 32420459
BMC Public Health. 2022 Apr 13;22(1):742
pubmed: 35418065
Lancet Child Adolesc Health. 2020 May;4(5):397-404
pubmed: 32272089
EClinicalMedicine. 2021 Jun;36:100924
pubmed: 34101770
J Med Microbiol. 2022 Aug;71(8):
pubmed: 35947525
Lancet Infect Dis. 2020 Nov;20(11):1263-1272
pubmed: 32679081
PLoS Comput Biol. 2022 May 27;18(5):e1010158
pubmed: 35622860
EClinicalMedicine. 2021 Jul;37:100954
pubmed: 34127960
BMC Public Health. 2021 Jun 5;21(1):1067
pubmed: 34090404
Lancet. 2020 Mar 14;395(10227):912-920
pubmed: 32112714

Auteurs

Bernadette C Young (BC)

Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: bernadette.young@ndm.ox.ac.uk.

David W Eyre (DW)

National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, UK; Big Data Institute, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

Saroj Kendrick (S)

Department of Health and Social Care, London, UK.

Chris White (C)

Department of Health and Social Care, London, UK.

Sylvester Smith (S)

Department of Health and Social Care, London, UK.

George Beveridge (G)

Department of Health and Social Care, London, UK.

Toby Nonnenmacher (T)

Department of Health and Social Care, London, UK.

Fegor Ichofu (F)

Department of Health and Social Care, London, UK.

Joseph Hillier (J)

Department of Health and Social Care, London, UK.

Sarah Oakley (S)

Microbiology Department, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.

Ian Diamond (I)

Office for National Statistics, Newport, UK.

Emma Rourke (E)

Office for National Statistics, Newport, UK.

Fiona Dawe (F)

Office for National Statistics, Newport, UK.

Ieuan Day (I)

Office for National Statistics, Newport, UK.

Lisa Davies (L)

Office for National Statistics, Newport, UK.

Paul Staite (P)

Office for National Statistics, Newport, UK.

Andrea Lacey (A)

Office for National Statistics, Newport, UK.

James McCrae (J)

Office for National Statistics, Newport, UK.

Ffion Jones (F)

Office for National Statistics, Newport, UK.

Joseph Kelly (J)

Office for National Statistics, Newport, UK.

Urszula Bankiewicz (U)

Office for National Statistics, Newport, UK.

Sarah Tunkel (S)

Department of Health and Social Care, London, UK.

Richard Ovens (R)

Deloitte MCS, London, UK.

David Chapman (D)

Deloitte MCS, London, UK.

Vineta Bhalla (V)

Deloitte MCS, London, UK.

Peter Marks (P)

Department of Health and Social Care, London, UK.

Nick Hicks (N)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; Department of Health and Social Care, London, UK; Public Health England, London, UK.

Tom Fowler (T)

William Harvey Research Institute, Queen Mary University of London, London, UK.

Susan Hopkins (S)

Public Health England, London, UK.

Lucy Yardley (L)

Health Protection Research Unit in Behavioural Science, University of Bristol, Bristol, UK; School of Psychology, University of Southampton, Southampton, UK.

Tim E A Peto (TEA)

Nuffield Department of Medicine, University of Oxford, Oxford, UK; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, University of Oxford, Oxford, UK; NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH